Highlights of ASH 2024

Clinical Highlights

Expert

Professor Timothy Hughes
Clinical Director, Precision Cancer Medicine Theme at SAHMRI,
Cancer Professor University of Adelaide,
Consultant Haematologist at the Royal Adelaide Hospital,
Adelaide, Australia

00:00 Welcome and Introduction
02:41 Update of ASCEND-CML study
06:47 ASC4FIRST Study week 96 update
12:12 Interim results from Phase 2 ASCESCALATE Trial
20:37 Olverembatinib as 2nd-line therapy in patients with chronic-phase CML

Resources

Update of the ASCEND-CML study of frontline asciminib: High rate of optimal response and resistance due to mutations (Yeung D et al.)

Asciminib demonstrates favorable safety and tolerability compared with each investigator-selected TKI in newly diagnosed CML-CP in the pivotal Phase 3 ASC4FIRST study: Week 96 update (Cortes J et al.)

Efficacy and safety of asciminib in CP-CML: Interim results from the Phase 2 ASCESCALATE trial in the cohort of patients after 1 prior TKI (Cortes J et al.)

18-months follow-up of the trial of imatinib after ponatinib induction (TIPI) in the front-line treatment of CP-CML (Nicolini F et al.)

Safety and efficacy of Tgrx-678, a BCR::ABL 1 allosteric inhibitor (Jiang Q et al.)

Olverembatinib as second-line therapy in patients with chronic-phase CML (Weiming L et al.) 

Biological Highlights

Expert

Professor Susan Branford
Head, Leukemia Unit, Genetics and Molecular Pathology,
SA Pathology
Adelaide (Australia)

00:00 Introduction
01:23 BCR::ABL1 protein degraders
06:41 Novel biomarkers of treatment-free remission
09:23 Blood cancer-related gene variants at diagnosis and treatment outcome
18:00 Questions and Answers (Clinical and biological)

Resources

BCR::ABL1 protein degraders

Abstract 4157: Targeting CML with potent and specific BCR::ABL1 degraders (Cruz-Rodriguez N et al.)

Abstract 1387: An orally active pan-BCR::ABL1 degrader Tgrx-3247 potentially targets a wide spectrum of orthosteric, allosteric and compound mutations resistant to TKI therapies (Wang Y et al.)

Novel biomarkers of treatment-free remission

Abstract 993: Increased inflammatory cytokines in plasma are associated with sustained treatment-free remission (Ross D et al.)

Blood cancer-related gene variants at diagnosis and treatment outcome

Abstract 991: Strong association between cancer gene variants at diagnosis, especially ASXL1, and emergence of kinase domain mutation-driven resistance in CML patients despite frontline treatment with more potent BCR::ABL inhibitors (Shanmunagathan N et al.)

Abstract 1774: The combination of asciminib with ATP competing TKIs might overcome the negative impact of ASXL1 mutations on molecular response in newly diagnosed CML patients (Ernst T et al.)